JP6157046B2 - 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 - Google Patents

静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 Download PDF

Info

Publication number
JP6157046B2
JP6157046B2 JP2010541564A JP2010541564A JP6157046B2 JP 6157046 B2 JP6157046 B2 JP 6157046B2 JP 2010541564 A JP2010541564 A JP 2010541564A JP 2010541564 A JP2010541564 A JP 2010541564A JP 6157046 B2 JP6157046 B2 JP 6157046B2
Authority
JP
Japan
Prior art keywords
domain
heterodimeric protein
charged amino
amino acid
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010541564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011508604A (ja
JP2011508604A5 (enExample
Inventor
カナン，グナセカラン
ウィッテキンド，マイケル
ヤン，ウェイ
ペントニー，マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2011508604A publication Critical patent/JP2011508604A/ja
Publication of JP2011508604A5 publication Critical patent/JP2011508604A5/ja
Application granted granted Critical
Publication of JP6157046B2 publication Critical patent/JP6157046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010541564A 2008-01-07 2009-01-06 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 Active JP6157046B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1956908P 2008-01-07 2008-01-07
US61/019,569 2008-01-07
US12030508P 2008-12-05 2008-12-05
US61/120,305 2008-12-05
PCT/US2009/000071 WO2009089004A1 (en) 2008-01-07 2009-01-06 Method for making antibody fc-heterodimeric molecules using electrostatic steering effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015215539A Division JP6328087B2 (ja) 2008-01-07 2015-11-02 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法

Publications (3)

Publication Number Publication Date
JP2011508604A JP2011508604A (ja) 2011-03-17
JP2011508604A5 JP2011508604A5 (enExample) 2013-11-14
JP6157046B2 true JP6157046B2 (ja) 2017-07-05

Family

ID=40578139

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010541564A Active JP6157046B2 (ja) 2008-01-07 2009-01-06 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP2015215539A Active JP6328087B2 (ja) 2008-01-07 2015-11-02 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP2018078924A Active JP6703560B2 (ja) 2008-01-07 2018-04-17 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃ ｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015215539A Active JP6328087B2 (ja) 2008-01-07 2015-11-02 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP2018078924A Active JP6703560B2 (ja) 2008-01-07 2018-04-17 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃ ｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法

Country Status (14)

Country Link
US (2) US8592562B2 (enExample)
EP (3) EP3061770B8 (enExample)
JP (3) JP6157046B2 (enExample)
AU (1) AU2009204501B2 (enExample)
CA (1) CA2709847C (enExample)
CY (1) CY1117162T1 (enExample)
DK (1) DK2235064T3 (enExample)
ES (2) ES2563027T3 (enExample)
HU (1) HUE028536T2 (enExample)
MX (1) MX350962B (enExample)
PL (1) PL2235064T3 (enExample)
PT (1) PT2235064E (enExample)
SI (1) SI2235064T1 (enExample)
WO (1) WO2009089004A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
JP2018138035A (ja) * 2008-01-07 2018-09-06 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃ ｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy

Families Citing this family (1405)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
EP3170835A1 (en) 2006-12-14 2017-05-24 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN109627287A (zh) 2007-02-23 2019-04-16 爱勒让治疗公司 三唑大环系统
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
CN101802015B (zh) 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
TWI464262B (zh) 2007-09-26 2014-12-11 中外製藥股份有限公司 抗體固定區的變異
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3415161A1 (en) 2008-06-26 2018-12-19 Acceleron Pharma Inc. The use of an actriib antagonist for the treatment of anemia
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2382228B2 (en) 2009-01-21 2026-01-07 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CN104262483A (zh) * 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
CN103755808B (zh) 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 抗-α5β1抗体及其应用
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
AU2013203859B2 (en) * 2009-04-27 2016-09-08 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2759233C (en) * 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US9308258B2 (en) 2009-07-08 2016-04-12 Amgen Inc. Stable and aggregation free antibody FC molecules through CH3 domain interface engineering
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011028952A1 (en) * 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
PH12012500691A1 (en) 2009-10-15 2012-11-12 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011047383A1 (en) 2009-10-16 2011-04-21 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2781539C (en) 2009-11-23 2021-07-20 Amgen Inc. Monomeric antibody fc
AU2010343056A1 (en) * 2009-12-29 2012-08-02 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CA2789154C (en) 2010-02-08 2024-06-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
RU2587619C2 (ru) 2010-02-18 2016-06-20 Дженентек, Инк. Антагонисты неурегулина и применение их в лечении злокачественного новообразования
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN107098958B (zh) 2010-03-26 2021-11-05 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
ES2537814T3 (es) 2010-04-09 2015-06-12 Amgen Inc. Proteínas, ácidos nucleicos, y anticuerpos BTNL9 y usos de los mismos
PL2560993T3 (pl) * 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
JP2019048814A (ja) * 2010-04-20 2019-03-28 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
AU2013203221B2 (en) * 2010-04-20 2016-06-02 Genmab A/S Heterodimeric antibody FC-containing proteins and methods for production thereof
AU2016219622A1 (en) * 2010-04-20 2016-09-15 Genmab A/S Heterodimeric antibody FC-containing proteins and methods for production thereof
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
EP2569337A1 (en) * 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
BR112012027995A2 (pt) 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
CN103097418A (zh) 2010-07-09 2013-05-08 霍夫曼-拉罗奇有限公司 抗神经毡蛋白抗体及使用方法
RU2013104039A (ru) 2010-07-19 2014-08-27 Ф. Хоффманн-Ля Рош Аг Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию
BR112013001429A2 (pt) 2010-07-19 2016-05-31 Hoffmann La Roche método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
JP5953303B2 (ja) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
EP2600895A1 (en) 2010-08-03 2013-06-12 Hoffmann-La Roche AG Chronic lymphocytic leukemia (cll) biomarkers
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
EP2600898A1 (en) 2010-08-05 2013-06-12 F.Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
CN103154038B (zh) 2010-08-13 2016-05-11 罗切格利卡特公司 抗成纤维细胞激活蛋白抗体及使用方法
CA2806640A1 (en) 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
RU2013110874A (ru) 2010-08-25 2014-09-27 Ф.Хоффманн-Ля Рош Аг Антитела против il-18r1 и их применения
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012031027A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
AU2011325833C1 (en) * 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
MX346500B (es) 2010-11-10 2017-03-22 Genentech Inc * Metodos y composiciones para inmunoterapia para enfermedad neural.
HRP20180421T1 (hr) 2010-11-17 2018-04-20 Chugai Seiyaku Kabushiki Kaisha Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
KR101923282B1 (ko) 2010-12-16 2018-11-28 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
PH12013501323A1 (en) 2010-12-20 2013-08-28 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
CA2820953A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
MX355255B (es) 2011-02-04 2018-04-11 Genentech Inc Variantes de fc y métodos para su producción.
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
US9499605B2 (en) 2011-03-03 2016-11-22 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
NZ608724A (en) * 2011-03-25 2015-12-24 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
HRP20181690T4 (hr) 2011-03-29 2025-01-03 Roche Glycart Ag Varijante protutijela fc
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
SI2697257T1 (sl) 2011-04-13 2017-02-28 Bristol-Myers Squibb Company FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
CA2832387A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
JP2014514313A (ja) 2011-04-20 2014-06-19 ロシュ グリクアート アクチェンゲゼルシャフト 血液脳関門のｐＨ依存性通過のための方法及び構築物
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
BR112013026266A2 (pt) 2011-05-16 2020-11-10 Genentech, Inc método de tratamento, anticorpos isolado e anti-fgfr1, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de diabetes em um indivíduo
CN103596984B (zh) 2011-06-15 2016-04-13 霍夫曼-拉罗奇有限公司 抗-人epo受体的抗体及使用方法
KR102049122B1 (ko) * 2011-06-30 2019-11-26 추가이 세이야쿠 가부시키가이샤 헤테로이량화 폴리펩티드
JP2014522843A (ja) 2011-06-30 2014-09-08 ジェネンテック， インコーポレイテッド 抗ｃ−ｍｅｔ抗体製剤
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
RU2014103185A (ru) 2011-07-18 2015-08-27 Артс Байолоджикс А/С Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
WO2013014208A2 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
RS66089B1 (sr) 2011-08-05 2024-11-29 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
RU2014109038A (ru) 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2013026833A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
DK2748202T3 (en) 2011-08-23 2018-09-17 Roche Glycart Ag BISPECIFIC ANTI-BINDING MOLECULES
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
RU2014114617A (ru) 2011-09-19 2015-10-27 Дженентек, Инк. Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf
US8987422B2 (en) 2011-09-22 2015-03-24 Amgen Inc. CD27L antigen binding proteins
HRP20230078T1 (hr) 2011-09-23 2023-05-12 Mereo Biopharma 5, Inc. Sredstva za vezivanje vegf/dll4 i njihova uporaba
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
CN108373506A (zh) 2011-10-14 2018-08-07 霍夫曼-拉罗奇有限公司 抗HtrA1抗体及使用方法
KR20140084164A (ko) 2011-10-15 2014-07-04 제넨테크, 인크. 암의 치료를 위한 scd1 길항제
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
ES2739808T3 (es) 2011-10-27 2020-02-04 Genmab As Producción de proteínas heterodiméricas
EA201490879A1 (ru) 2011-10-28 2014-08-29 Дженентек, Инк. Терапевтические комбинации и способы лечения меланомы
RU2681885C2 (ru) * 2011-10-31 2019-03-13 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула с регулируемой конъюгацией между тяжелой цепью и легкой цепью
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
EP2782932A1 (en) 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Purification of anti-c-met antibodies
CA2854921A1 (en) 2011-11-23 2013-05-30 Amgen Inc. Methods of treatment using an antibody against interferon gamma
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
WO2013096221A1 (en) 2011-12-21 2013-06-27 Amgen Inc. Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
HK1200849A1 (en) 2011-12-22 2015-08-14 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
CN113896787A (zh) 2011-12-22 2022-01-07 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
CA3125875A1 (en) 2011-12-22 2013-06-27 F.Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
CN102558355B (zh) * 2011-12-31 2015-02-25 苏州康宁杰瑞生物科技有限公司 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
US20130183294A1 (en) 2012-01-18 2013-07-18 Genentech, Inc. Methods of using fgf19 modulators
US9200072B2 (en) 2012-01-18 2015-12-01 Genentech Inc. Anti-LRP5 antibodies and methods of use
CA2862745A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2861031C (en) 2012-02-03 2022-10-25 Carole BOURQUIN Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
EP2812350B1 (en) 2012-02-11 2019-04-03 F.Hoffmann-La Roche Ag R-spondin translocations and methods using the same
BR112014018005B1 (pt) 2012-02-15 2021-06-29 F. Hoffmann-La Roche Ag Uso de um complexo não covalente imobilizado
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR090903A1 (es) 2012-05-01 2014-12-17 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17
KR20150008171A (ko) * 2012-05-10 2015-01-21 자임워크스 인코포레이티드 단일군 일가 항체 구조물 및 그의 용도
ES2843054T3 (es) * 2012-05-10 2021-07-15 Zymeworks Inc Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
TW201400132A (zh) 2012-05-21 2014-01-01 Genentech Inc 改善血腦屏障運送之安全性之方法
CN104335047B (zh) 2012-05-23 2017-08-15 弗·哈夫曼-拉罗切有限公司 治疗剂的选择方法
EP2862875B1 (en) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
KR20150023711A (ko) 2012-06-15 2015-03-05 제넨테크, 인크. 항-pcsk9 항체, 제제, 투여, 및 사용 방법
FI3421486T3 (fi) 2012-06-22 2023-12-15 Dartmouth College Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
BR112014030843A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
CN107973856B (zh) 2012-07-04 2021-11-23 弗·哈夫曼-拉罗切有限公司 共价连接的抗原-抗体缀合物
MX356162B (es) 2012-07-05 2018-05-16 Genentech Inc Sistema de expresion y secrecion.
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
JP2015523380A (ja) 2012-07-09 2015-08-13 ジェネンテック， インコーポレイテッド 抗ｃｄ７９ｂ抗体を含む免疫複合体
PE20150614A1 (es) 2012-07-09 2015-05-25 Genentech Inc Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
TW201408696A (zh) 2012-07-09 2014-03-01 Genentech Inc 抗ｃｄ２２抗體及免疫結合物
EP2869849A1 (en) 2012-07-09 2015-05-13 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
HK1207575A1 (en) * 2012-07-13 2016-02-05 Zymeworks, Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
CN104583230A (zh) 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
MX366178B (es) 2012-07-19 2019-07-01 Amgen Inc Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
CN102851338A (zh) * 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
EP3434695B1 (en) 2012-08-07 2020-12-02 Roche Glycart AG Improved immunotherapy
MX2015001678A (es) 2012-08-09 2015-08-14 Roche Glycart Ag Anticuerpos asgpr y sus usos.
KR102854939B1 (ko) 2012-08-24 2025-09-03 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
EP3401337A1 (en) 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EA201590640A1 (ru) 2012-09-27 2015-11-30 Мерюс Б.В. БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА КЛАССА IgG В КАЧЕСТВЕ РЕКРУТЕРОВ Т-КЛЕТОК
JP6581505B2 (ja) 2012-10-03 2019-09-25 ザイムワークス，インコーポレイテッド 重鎖および軽鎖ポリペプチドの対を定量化する方法
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
CN104704004B (zh) 2012-10-08 2019-12-31 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CA2890575C (en) 2012-11-05 2021-11-09 Jumpei Enami Antibody and antibody composition production method
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
KR20150064205A (ko) 2012-11-08 2015-06-10 에프. 호프만-라 로슈 아게 Her3의 베타-헤어핀에 결합하는 her3 항원 결합 단백질
CN104968367B (zh) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN112079929A (zh) * 2012-11-21 2020-12-15 武汉友芝友生物制药有限公司 双特异性抗体
EP2927321B1 (en) * 2012-11-27 2021-02-17 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
CA3206122A1 (en) 2012-11-28 2014-06-05 Zymeworks Bc Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014104165A1 (ja) 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
SG11201505286TA (en) 2013-01-10 2015-08-28 Genmab Bv Human igg1 fc region variants and uses thereof
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) * 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2900764A1 (en) * 2013-02-08 2014-08-14 Stemcentrx, Inc. Novel multispecific constructs
WO2014126871A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
ES2751735T3 (es) 2013-02-12 2020-04-01 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
KR101989551B1 (ko) * 2013-02-15 2019-09-30 알-팜 인터내셔널, 엘엘씨. IL-1β 억제제 조성물 및 이의 용도
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2896259A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Anti-mcsp antibodies
KR20150122203A (ko) 2013-02-26 2015-10-30 로슈 글리카트 아게 T 세포 활성화 이중특이적 항원 결합 분자
EA031214B1 (ru) 2013-02-26 2018-12-28 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
EP2975061A4 (en) * 2013-03-13 2017-03-01 Ibentrus Inc. Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
BR112015022019A2 (pt) 2013-03-14 2017-08-29 Genentech Inc Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
CN105246508A (zh) 2013-03-14 2016-01-13 基因泰克公司 Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA2906526C (en) 2013-03-15 2022-12-06 Ellen Chi Interferon alpha and omega antibody antagonists
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
BR112015020290A2 (pt) 2013-03-15 2017-10-10 Genentech Inc métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
TW201522374A (zh) 2013-03-15 2015-06-16 Genentech Inc 抗ｃｒｔｈ２抗體及使用方法
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
KR102211176B1 (ko) * 2013-03-15 2021-02-01 젠코어 인코포레이티드 이형이량체 단백질
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
CN105229032A (zh) 2013-03-18 2016-01-06 比奥塞罗克斯产品公司 人源化抗cd134(ox40)抗体及其应用
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
AU2014261630B2 (en) 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
AU2014261631B2 (en) 2013-04-29 2019-02-14 F. Hoffmann-La Roche Ag FcRn-binding abolished anti-IGF-1R antibodies and their use in the treatment of vascular eye diseases
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
EP4324480A3 (en) 2013-05-20 2024-05-08 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
TR201815608T4 (tr) 2013-05-30 2018-11-21 Kiniksa Pharmaceuticals Ltd Onkastatin m reseptörü antijeni bağlayıcı proteinler.
US10465006B2 (en) 2013-07-05 2019-11-05 Genmab A/S Humanized or chimeric CD3 antibodies
MX369152B (es) 2013-07-31 2019-10-30 Amgen Inc Construcciones del factor de diferenciación de crecimiento 15 (gdf-15).
CN105722855B (zh) * 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
RU2016109247A (ru) 2013-09-17 2017-10-19 Дженентек, Инк. Способы применения антител к lgr5
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
KR102441231B1 (ko) * 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
CA2926084A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
US20150147333A1 (en) 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use
AU2014340129A1 (en) 2013-10-23 2016-05-26 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
WO2015069865A1 (en) 2013-11-06 2015-05-14 Janssen Biotech, Inc. Anti-ccl17 antibodies
JP2016538283A (ja) 2013-11-13 2016-12-08 ザイムワークス，インコーポレイテッド Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
RS60882B1 (sr) 2013-11-21 2020-11-30 Hoffmann La Roche Anti-alfa-sinukleinska antitela i postupci za njihovu primenu
JP6817064B2 (ja) 2013-11-27 2021-01-20 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
KR20160098328A (ko) 2013-12-13 2016-08-18 제넨테크, 인크. 항-cd33 항체 및 면역접합체
JP6608827B2 (ja) 2013-12-20 2019-11-20 エフ．ホフマン−ラ ロシュ アーゲー ヒト化抗タウ（ｐＳ４２２）抗体及び使用方法
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
SG10201912797XA (en) 2013-12-24 2020-02-27 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
BR112016012666A2 (pt) 2014-01-03 2017-09-26 Hoffmann La Roche conjugado, anticorpos, formulação farmacêutica e usos de conjugado
RU2693438C2 (ru) 2014-01-03 2019-07-02 Ф. Хоффманн-Ля Рош Аг Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
JP6521464B2 (ja) 2014-01-03 2019-05-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合で連結されたポリペプチド毒素−抗体コンジュゲート
EP3092251B1 (en) 2014-01-06 2021-01-20 F. Hoffmann-La Roche AG Monovalent blood brain barrier shuttle modules
AU2014377106B2 (en) 2014-01-08 2019-10-03 Jiangsu Hengrui Medicine Co., Ltd. IL-15 heterodimeric protein and uses thereof
CN105916880B (zh) 2014-01-15 2020-01-17 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
EP3094647A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
BR112016015693A2 (pt) 2014-01-24 2017-10-24 Genentech Inc método para tratar um câncer de próstata e anticorpo
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015213741B2 (en) 2014-02-08 2020-10-08 Genentech, Inc. Methods of treating Alzheimer's Disease
KR20160111039A (ko) 2014-02-08 2016-09-23 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
LT3105253T (lt) 2014-02-12 2018-09-10 F. Hoffmann-La Roche Ag Antikūnai prieš jagged1 ir jų naudojimo būdai
AU2015218631A1 (en) 2014-02-21 2016-08-11 Genentech, Inc. Anti-IL-13/IL-17 bispecific antibodies and uses thereof
NZ724013A (en) 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
SG10201913289TA (en) 2014-02-28 2020-02-27 Merus Nv Antibody that binds erbb-2 and erbb-3
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
ES2770684T3 (es) 2014-03-14 2020-07-02 Novartis Ag Moléculas de anticuerpos contra LAG-3 y usos de los mismos
US10435694B2 (en) 2014-03-14 2019-10-08 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
JP6637439B2 (ja) 2014-03-31 2020-01-29 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US20170022291A1 (en) 2014-04-01 2017-01-26 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3126389B1 (en) 2014-04-02 2024-10-23 F. Hoffmann-La Roche AG Method for detecting multispecific antibody light chain mispairing
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US20190202908A1 (en) * 2014-04-15 2019-07-04 President And Fellows Of Harvard College Bi-specific agents
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
AU2015252866B2 (en) * 2014-05-02 2021-01-28 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
KR102603417B1 (ko) 2014-05-06 2023-11-20 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
WO2015175375A1 (en) 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
JP6868394B2 (ja) * 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
CN106414499A (zh) 2014-05-22 2017-02-15 基因泰克公司 抗gpc3抗体和免疫偶联物
CN106661622B (zh) 2014-05-23 2020-08-21 豪夫迈·罗氏有限公司 Mit生物标志物和使用它们的方法
AU2015265457B2 (en) 2014-05-28 2021-02-18 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
AU2015269333B2 (en) 2014-06-04 2020-05-07 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
BR112016028838A2 (pt) 2014-06-11 2017-10-24 Genentech Inc anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
CN107073109B (zh) 2014-06-11 2021-08-06 凯西·A·格林 Vista激动剂和拮抗剂抑制或增强体液免疫的用途
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
JP6654581B2 (ja) 2014-06-26 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｂｒｄｕ抗体および使用方法
CA2952727A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific nkp46 binding proteins
WO2015197598A2 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CN106574270B (zh) 2014-07-03 2021-07-13 豪夫迈·罗氏有限公司 多肽表达系统
CN107074925B (zh) 2014-07-10 2021-08-24 阿费里斯股份公司 用于预防和/或治疗亨廷顿氏病的物质和方法
MY188940A (en) 2014-07-11 2022-01-13 Ventana Med Syst Inc Anti-pd-l1 antibodies and diagnostic uses thereof
MX370807B (es) 2014-07-11 2020-01-08 Genmab As Anticuerpos que se unen a axl.
RU2017103289A (ru) 2014-07-11 2018-08-14 Дженентек, Инк. Ингибирование пути notch
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US9777073B2 (en) * 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3172234B1 (en) 2014-07-21 2020-04-08 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
MD20170020A2 (ro) 2014-07-30 2017-07-31 Ngm Biopharmaceuticals, Inc. Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CN106661120B (zh) * 2014-08-04 2021-10-01 豪夫迈·罗氏有限公司 双特异性t细胞活化性抗原结合分子
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
AU2015305531B2 (en) 2014-08-19 2021-05-20 Novartis Ag Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
US20170260261A1 (en) 2014-08-28 2017-09-14 Bioatla, Llc Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
EP3189152A4 (en) 2014-09-03 2018-04-04 BioAtla LLC Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
MA40608A (fr) 2014-09-09 2016-03-17 Janssen Biotech Inc Polythérapies avec des anticorps anti-cd38
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
KR20170066421A (ko) 2014-09-12 2017-06-14 제넨테크, 인크. 항-cll-1 항체 및 면역접합체
PT3191135T (pt) 2014-09-12 2020-11-12 Genentech Inc Anticorpos anti-her2 e imunoconjugados
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
CA2957148A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
US20160082120A1 (en) 2014-09-23 2016-03-24 Genentech, Inc. METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
US20170247476A1 (en) 2014-09-25 2017-08-31 Amgen Inc. Protease-activatable bispecific proteins
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP7372728B2 (ja) 2014-10-31 2023-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改変ｔ細胞に関する方法および組成物
RU2017119009A (ru) 2014-11-03 2018-12-05 Дженентек, Инк. Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения
JP2017536842A (ja) 2014-11-03 2017-12-14 ジェネンテック， インコーポレイテッド Ｏｘ４０アゴニスト治療薬の有効性及び評価を予測するための方法及びバイオマーカー
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
HRP20191766T1 (hr) 2014-11-06 2019-12-27 F. Hoffmann - La Roche Ag Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene
EP3842453A1 (en) 2014-11-06 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and protein a-binding properties
WO2016077369A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Animal model for nephropathy and agents for treating the same
SG11201703767XA (en) 2014-11-10 2017-06-29 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
SG11201703597TA (en) 2014-11-14 2017-06-29 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
JP6944369B2 (ja) 2014-11-20 2021-10-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｔ細胞活性化二重特異性抗原結合分子ｃｄ３ ａｂｄ葉酸受容体１（ｆｏｌｒ１）及びｐｄ−１軸結合アンタゴニストの併用療法
MA40972B1 (fr) 2014-11-20 2020-11-30 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
PT3221357T (pt) 2014-11-20 2020-07-28 Hoffmann La Roche Cadeias leves comuns e métodos de utilização
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
MX2017006918A (es) 2014-11-26 2018-01-25 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38.
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2968258A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
AU2015358325A1 (en) 2014-12-05 2017-05-25 Genentech, Inc. Anti-CD79b antibodies and methods of use
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
CN107207591A (zh) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 血脑屏障受体抗体及使用方法
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
JP2018503368A (ja) 2014-12-18 2018-02-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EP3233907B1 (en) * 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
CN113045650A (zh) 2014-12-19 2021-06-29 中外制药株式会社 抗-c5抗体及使用方法
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
EA201791554A1 (ru) 2015-01-08 2017-12-29 Генмаб А/С Биспецифичные антитела против cd3 и cd20
CN110658340B (zh) * 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
ES2947589T3 (es) 2015-01-31 2023-08-11 Univ Pennsylvania Composiciones y métodos para el suministro de moléculas terapéuticas a linfocitos T
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
EP3262217A4 (en) 2015-02-24 2018-07-18 BioAtla LLC Conditionally active biological proteins
WO2016141110A1 (en) 2015-03-03 2016-09-09 Schlumberger Technology Corporation Multi-mode acoustic tool and method
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
EP3265557B1 (en) 2015-03-06 2019-10-16 F. Hoffmann-La Roche AG Ultrapurified dsba and dsbc and methods of making and using the same
JP2018511797A (ja) 2015-03-16 2018-04-26 ジェネンテック， インコーポレイテッド ＩＬ−１３の検出方法及び定量方法並びにＴｈ２関連疾患の診断及び治療における使用
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3274457A4 (en) * 2015-03-26 2018-08-08 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MX2017012352A (es) 2015-04-03 2018-01-26 Eureka Therapeutics Inc Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
EP3280727B1 (en) 2015-04-06 2021-02-17 Acceleron Pharma Inc. Single-arm type i and type ii receptor fusion proteins and uses thereof
JP6955445B2 (ja) 2015-04-07 2021-10-27 ジェネンテック， インコーポレイテッド アゴニスト性の活性を有する抗原結合複合体及びその使用方法
ES2899227T3 (es) 2015-04-07 2022-03-10 Alector Llc Anticuerpos anti sortilina y métodos de uso de los mismos
CA2981751A1 (en) 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
TN2017000432A1 (en) 2015-04-10 2019-04-12 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
US10787500B2 (en) 2015-04-10 2020-09-29 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CN108064245A (zh) 2015-04-17 2018-05-22 埃尔萨里斯生物技术公司 抗Tyro3抗体及其用途
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP7044553B2 (ja) 2015-04-24 2022-03-30 ジェネンテック， インコーポレイテッド 結合ポリペプチドを含む細菌を特定する方法
CN107787332B (zh) 2015-04-24 2022-09-09 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
EP4450524A3 (en) 2015-05-11 2025-05-14 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
IL295002A (en) 2015-05-12 2022-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
EP4553157A3 (en) 2015-05-20 2025-07-23 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
EP3303400B1 (en) 2015-05-28 2020-09-09 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
ES2789500T5 (es) 2015-05-29 2023-09-20 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
EP3302563A1 (en) 2015-05-29 2018-04-11 H. Hoffnabb-La Roche Ag Humanized anti-ebola virus glycoprotein antibodies and methods of use
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
CN107810011A (zh) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 使用抗ox40抗体治疗癌症的方法
AU2016274584A1 (en) 2015-06-08 2018-01-04 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
WO2016205176A1 (en) 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
MA42428B1 (fr) 2015-06-16 2023-10-31 Hoffmann La Roche Anticorps humanisés et à maturation d'affinité dirigés contre fcrh5 et méthodes d'utilisation
KR20180012859A (ko) 2015-06-17 2018-02-06 제넨테크, 인크. 항-her2 항체 및 이용 방법
UA125115C2 (uk) 2015-06-22 2022-01-12 Янссен Байотек, Інк. Спосіб лікування суб'єкта, який має множинну мієлому (мм)
JP6971153B2 (ja) 2015-06-23 2021-11-24 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的ｎｋエンゲイジャータンパク質
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
JP7021955B2 (ja) 2015-06-24 2022-03-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
MX388164B (es) 2015-06-24 2025-03-19 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista
EP3313877B1 (en) 2015-06-24 2020-06-03 H. Hoffnabb-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
WO2016207124A1 (en) 2015-06-25 2016-12-29 F. Hoffmann-La Roche Ag Cell based assay for determining antibody or ligand binding and function
ES2898065T3 (es) 2015-06-29 2022-03-03 Ventana Med Syst Inc Materiales y procedimientos para realizar ensayos histoquímicos para proepirregulina y anfirregulina humanas
KR20180021864A (ko) 2015-06-29 2018-03-05 제넨테크, 인크. 장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017005649A1 (en) 2015-07-09 2017-01-12 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
EP3115376B1 (en) 2015-07-10 2018-09-05 Merus N.V. Human cd3 binding antibody
CN108368171A (zh) 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
UA128057C2 (uk) 2015-07-15 2024-03-27 Ґенмаб А/С Гуманізоване або химерне антитіло, яке зв'язує cd3 людини
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
KR102761886B1 (ko) 2015-07-30 2025-02-06 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
CN107921128B (zh) 2015-08-05 2022-04-26 詹森生物科技公司 抗cd154抗体及其使用方法
EA034582B1 (ru) 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP4209499B1 (en) 2015-08-13 2024-08-07 Amgen Inc. Charged depth filtration of antigen-binding proteins
CN107106682B (zh) 2015-08-26 2021-05-25 比森医疗股份有限公司 多特异性抗体平台和相关方法
US11649435B2 (en) 2015-08-28 2023-05-16 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN108135932A (zh) 2015-08-28 2018-06-08 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
JP2018526034A (ja) 2015-09-10 2018-09-13 アフィジェン・インコーポレイテッド 腫瘍治療薬の配列決定により導かれる選択
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
EP3350216A1 (en) 2015-09-15 2018-07-25 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
WO2017046994A1 (en) 2015-09-18 2017-03-23 Chugai Seiyaku Kabushiki Kaisha Il-8-binding antibodies and uses thereof
JP6904947B2 (ja) 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
IL257565B2 (en) 2015-09-23 2024-08-01 Genentech Inc Optimized variants of anti-vegf antibodies
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
US11142565B2 (en) 2015-09-24 2021-10-12 Abvitro Llc Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
HUE069796T2 (hu) 2015-09-25 2025-04-28 Hoffmann La Roche Anti-TIGIT ellenanyagok és alkalmazásukra szolgáló eljárások
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN108137699B (zh) 2015-10-02 2022-05-27 豪夫迈·罗氏有限公司 对pd1和tim3特异性的双特异性抗体
ES2895034T3 (es) 2015-10-02 2022-02-17 Hoffmann La Roche Anticuerpos anti-PD1 y procedimientos de uso
US20170129962A1 (en) * 2015-10-02 2017-05-11 Hoffmann-La Roche Inc. Multispecific antibodies
CN108139394B (zh) 2015-10-02 2020-10-30 豪夫迈·罗氏有限公司 用于确定同时结合的基于细胞的fret测定法
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
JP2018533930A (ja) 2015-10-02 2018-11-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｔ細胞活性化抗原結合分子
AR106365A1 (es) 2015-10-02 2018-01-10 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
MA43025A (fr) 2015-10-02 2021-05-26 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
WO2017055398A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
EP3150637A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Multispecific antibodies
WO2017055395A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
JP6937746B2 (ja) 2015-10-02 2021-09-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｄ１９×ｃｄ３ｔ細胞活性化抗原結合分子
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
CR20180171A (es) 2015-10-07 2018-05-03 Hoffmann La Roche Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
KR20180069839A (ko) 2015-10-08 2018-06-25 자임워크스 인코포레이티드 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
MD3365373T2 (ro) 2015-10-23 2021-08-31 Merus Nv Molecule de legare care inhibă dezvoltarea cancerului
CA3000048A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
BR112018007703A2 (pt) 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
BR112018011100A2 (en) 2015-12-01 2018-12-04 Genmab B.V. antibody, composition, nucleic acid construct, expression vector, host cell, method for treating an individual having a cancer, kit of parts, and use of an antibody or composition.
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
PL3387015T3 (pl) 2015-12-09 2022-02-14 F. Hoffmann-La Roche Ag Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN106883297B (zh) 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
CN108713027A (zh) 2015-12-17 2018-10-26 詹森生物科技公司 特异性结合hla-dr的抗体及其用途
AU2016369623A1 (en) 2015-12-17 2018-06-28 Novartis Ag Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
ES2969440T3 (es) 2015-12-18 2024-05-20 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
KR20230027321A (ko) 2015-12-18 2023-02-27 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EP4643874A2 (en) 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
WO2017117179A1 (en) * 2015-12-28 2017-07-06 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
JP6949030B2 (ja) 2016-01-08 2021-10-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
EP3405489A1 (en) 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
MX2018010361A (es) 2016-02-29 2019-07-08 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
RS64266B1 (sr) 2016-03-22 2023-07-31 Hoffmann La Roche Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom
BR112018016281A2 (pt) 2016-03-22 2019-01-02 F. Hoffmann-La Roche Ag molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
WO2017181111A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
KR20180134385A (ko) 2016-04-15 2018-12-18 노파르티스 아게 선택적 단백질 발현을 위한 조성물 및 방법
KR102697688B1 (ko) 2016-04-15 2024-08-21 바이오아트라, 인코퍼레이티드 항 Axl항체 및 이의 면역접합체와 이것들의 용도
NZ746658A (en) 2016-04-15 2025-09-26 Immunext Inc Anti-human vista antibodies and use thereof
US11512144B2 (en) 2016-04-20 2022-11-29 Regeneran Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing loci
IL262268B2 (en) 2016-04-20 2024-05-01 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
TW202402326A (zh) 2016-04-28 2024-01-16 日商中外製藥股份有限公司 含抗體製劑
JP6675017B2 (ja) 2016-05-02 2020-04-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ コントースボディ−単鎖標的結合物質
NZ775714A (en) 2016-05-04 2024-12-20 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
JP7285076B2 (ja) 2016-05-11 2023-06-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
PL3455261T3 (pl) 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
CN109312408B (zh) 2016-05-17 2022-12-23 豪夫迈·罗氏有限公司 用于诊断和供免疫疗法中使用的基质基因签名
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
US11623964B2 (en) 2016-05-23 2023-04-11 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
KR102523402B1 (ko) 2016-06-14 2023-04-19 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
JP6196411B1 (ja) 2016-06-17 2017-09-13 中外製薬株式会社 抗ミオスタチン抗体および使用方法
HUE068564T2 (hu) 2016-06-17 2025-01-28 Hoffmann La Roche Multispecifikus antitestek tisztítása
WO2017223405A1 (en) 2016-06-24 2017-12-28 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3474895A1 (en) 2016-06-28 2019-05-01 UMC Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
EA201990293A1 (ru) 2016-07-14 2019-07-31 Генмаб А/С Мультиспецифичные антитела против cd40 и cd137
RS62011B1 (sr) 2016-07-15 2021-07-30 Acceleron Pharma Inc Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201900373WA (en) * 2016-07-19 2019-02-27 Ibentrus Inc Bispecific proteins and methods for preparing same
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN109563125B (zh) 2016-07-22 2022-08-09 美国安进公司 含有Fc的蛋白的纯化方法
HUE067225T2 (hu) 2016-07-27 2024-10-28 Acceleron Pharma Inc Mielofibrózis kezelésére szolgáló készítmények
KR20230100748A (ko) 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
WO2018021450A1 (ja) 2016-07-29 2018-02-01 中外製薬株式会社 増強されたｆｖｉｉｉ補因子機能代替活性を有する二重特異性抗体
EP3490590A2 (en) 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018026942A1 (en) * 2016-08-02 2018-02-08 Merrimack Pharmaceuticals, Inc. Heteromeric polypeptides
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
MX386014B (es) 2016-08-10 2025-03-18 Univ Ajou Ind Academic Coop Found Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018038046A1 (ja) 2016-08-22 2018-03-01 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
CN109715201A (zh) 2016-09-23 2019-05-03 豪夫迈·罗氏有限公司 Il-13拮抗剂用于治疗特应性皮炎的用途
PE20190576A1 (es) 2016-09-29 2019-04-22 Beijing Hanmi Pharmaceutical Co Ltd Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas
CN109791149A (zh) 2016-09-30 2019-05-21 豪夫迈·罗氏有限公司 用于功能分析多特异性分子的基于spr的双重结合测定法
ES2897217T3 (es) 2016-09-30 2022-02-28 Hoffmann La Roche Anticuerpos biespecíficos frente a p95HER2
JP7219705B2 (ja) 2016-10-05 2023-02-08 アクセルロン ファーマ インコーポレイテッド ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
CN116650622A (zh) 2016-10-05 2023-08-29 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
CA3039525A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
KR102804118B1 (ko) 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3526241A1 (en) 2016-10-14 2019-08-21 Xencor, Inc. Il15/il15r heterodimeric fc-fusion proteins
KR20250044934A (ko) 2016-10-19 2025-04-01 인벤라 인코포레이티드 항체 구조물
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
CN110461868A (zh) 2016-11-01 2019-11-15 根马布私人有限公司 多肽变体及其用途
CN110312523B (zh) 2016-11-08 2024-04-26 齐鲁皮吉特湾生物治疗有限公司 抗pd1和抗ctla4抗体
EP3538123A4 (en) 2016-11-10 2020-10-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE
EP3538555A1 (en) 2016-11-14 2019-09-18 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
MX2019005858A (es) 2016-11-18 2019-08-12 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo.
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
US20230192896A1 (en) 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
EP3555620A1 (en) 2016-12-13 2019-10-23 H. Hoffnabb-La Roche Ag Method to determine the presence of a target antigen in a tumor sample
MX2019006955A (es) 2016-12-19 2019-08-01 Hoffmann La Roche Terapia de combinacion con agonistas de 4-1bb orientados (cd137).
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
CN110100007B (zh) 2016-12-21 2024-05-28 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的酶的再使用
WO2018114877A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
JP7215999B2 (ja) 2016-12-21 2023-01-31 エフ．ホフマン－ラ ロシュ アーゲー 抗体またはリガンドの結合および機能を決定するためのアッセイ法
CN110088292A (zh) 2016-12-21 2019-08-02 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3559032A1 (en) 2016-12-23 2019-10-30 Innate Pharma Heterodimeric antigen binding proteins
BR112019013189A2 (pt) 2017-01-03 2019-12-10 Hoffmann La Roche moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa
US11220531B2 (en) 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs
WO2018132597A1 (en) 2017-01-12 2018-07-19 Eureka Therapeutics, Inc. Constructs targeting histone h3 peptide/mhc complexes and uses thereof
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110234355B (zh) 2017-02-01 2021-11-09 浙江时迈药业有限公司 单体人IgG1 Fc和双特异性抗体
AU2018218753A1 (en) 2017-02-07 2019-09-26 Daiichi Sankyo Company, Limited Anti-GPRC5D antibody and molecule containing same
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
UA128814C2 (uk) 2017-02-10 2024-10-30 Генмаб Б.В. Поліпептид та його застосування
CA3054642A1 (en) * 2017-02-10 2018-08-16 Dragonfly Therapeutics, Inc. Proteins binding bcma, nkg2d and cd16
CN110494453B (zh) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
EP3586872A4 (en) * 2017-02-24 2020-12-30 Chugai Seiyaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION, ANTIGEN BINDING MOLECULES, METHOD OF TREATMENT AND METHOD OF SCREENING
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
US11685776B2 (en) 2017-03-02 2023-06-27 Novartis Ag Engineered heterodimeric proteins
EP3592769B1 (en) 2017-03-09 2024-05-08 Genmab A/S Antibodies against pd-l1
MA48723A (fr) * 2017-03-10 2020-04-08 Hoffmann La Roche Procédé de production d'anticorps multispécifiques
CN110891611B (zh) 2017-03-22 2024-03-29 阿森迪斯制药公司 水凝胶交联透明质酸前药组合物和方法
CR20190481A (es) 2017-03-22 2020-01-06 Genentech Inc Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares
KR20190133162A (ko) 2017-03-28 2019-12-02 제넨테크, 인크. 신경퇴행성 질병의 치료 방법
CN110382542B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
EP3601345A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
IL269645B2 (en) 2017-03-31 2025-05-01 Genmab Holding B V Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
WO2018177324A1 (zh) 2017-04-01 2018-10-04 北京韩美药品有限公司 抗pd‐l1/抗pd‐1天然抗体结构样异源二聚体形式双特异抗体及其制备
EP3606947B1 (en) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
MX2019011858A (es) 2017-04-03 2019-11-21 Oncologie Inc Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
MX2019011770A (es) 2017-04-03 2020-01-09 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
BR112019017753B1 (pt) 2017-04-04 2024-04-30 F. Hoffmann-La Roche Ag Molécula biespecífica de ligação ao antígeno, composição farmacêutica e uso da molécula biespecífica de ligação ao antígeno
EP4516809A3 (en) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
PL3606954T3 (pl) 2017-04-05 2022-10-17 F. Hoffmann-La Roche Ag Przeciwciała anty-LAG3
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
JP2020516638A (ja) 2017-04-13 2020-06-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20190078160A1 (en) 2017-04-21 2019-03-14 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
SG10201913582XA (en) 2017-04-26 2020-02-27 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
BR112019024230A2 (pt) 2017-05-17 2020-06-09 Merus N.V. combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
MX2019014407A (es) 2017-06-07 2020-02-05 Genmab Bv Anticuerpos terapeuticos basados en hexameros de inmunoglobulina g (igg) mutados.
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
KR20240147708A (ko) 2017-07-11 2024-10-08 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 작동자 항체 및 이의 용도
US20200172617A1 (en) 2017-07-20 2020-06-04 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
KR20240006698A (ko) 2017-07-21 2024-01-15 제넨테크, 인크. 암에 대한 치료 및 진단 방법
AU2018308364C1 (en) 2017-07-26 2023-02-16 Forty Seven, LLC Anti-SIRP-alpha antibodies and related methods
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
HUE071182T2 (hu) 2017-08-09 2025-08-28 Merus Nv EGFR és CMET kötõ antitestek
MX2020000903A (es) 2017-08-11 2020-07-22 Genentech Inc Anticuerpos anti-cd8 y usos de los mismos.
SG11202001311VA (en) 2017-08-22 2020-03-30 Sanabio Llc Soluble interferon receptors and uses thereof
MY204641A (en) 2017-09-29 2024-09-06 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
JP2020536967A (ja) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
AU2018353420A1 (en) 2017-10-20 2020-04-16 F. Hoffmann-La Roche Ag Method for generating multispecific antibodies from monospecific antibodies
CN111372947B (zh) * 2017-10-30 2025-08-15 豪夫迈·罗氏有限公司 在体内从单特异性抗体产生多特异性抗体的方法
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
JP2021500930A (ja) 2017-11-01 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｐボディ−多価標的結合物質
EP3703746A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Novel tnf family ligand trimer-containing antigen binding molecules
US12227594B2 (en) 2017-11-01 2025-02-18 Hoffmann-La Roche Inc. Bispecific 2+1 contorsbodies
KR102559706B1 (ko) 2017-11-01 2023-07-25 에프. 호프만-라 로슈 아게 Trifab-콘톨스바디
CN111315781A (zh) 2017-11-01 2020-06-19 豪夫迈·罗氏有限公司 用靶向性ox40激动剂的组合疗法
CR20240273A (es) 2017-11-01 2024-08-27 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229)
PL3707510T3 (pl) 2017-11-06 2024-09-30 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
EP4640703A2 (en) 2017-11-14 2025-10-29 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
KR20200089286A (ko) 2017-11-16 2020-07-24 노파르티스 아게 조합 요법
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019101695A1 (en) 2017-11-21 2019-05-31 Innate Pharma Multispecific antigen binding proteins
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
WO2019122052A2 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Antibodies binding to hla-a2/wt1
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
US11945839B2 (en) 2017-12-22 2024-04-02 Hoffmann-La Roche Inc. Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
KR102845020B1 (ko) 2017-12-28 2025-08-12 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
JP7369127B2 (ja) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
CN119431582A (zh) 2017-12-29 2025-02-14 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
EP3731865A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
CA3087537A1 (en) 2018-01-04 2019-07-11 Jan-willem THEUNISSEN Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
CN111801580B (zh) 2018-01-12 2024-08-23 建新公司 用于定量多肽的方法
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
EP3740505A1 (en) 2018-01-16 2020-11-25 Lakepharma Inc. Bispecific antibody that binds cd3 and another target
WO2019145455A1 (en) 2018-01-24 2019-08-01 Genmab B.V. Polypeptide variants and uses thereof
CN111630063A (zh) 2018-01-31 2020-09-04 豪夫迈·罗氏有限公司 稳定化的免疫球蛋白结构域
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
JP2021512914A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
MX2020008291A (es) 2018-02-09 2020-09-25 Genentech Inc Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos.
AU2019218433A1 (en) 2018-02-11 2020-09-03 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
US20200399373A1 (en) 2018-02-14 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule and combination
SG11202007945UA (en) 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019175198A2 (en) 2018-03-12 2019-09-19 Genmab A/S Antibodies
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
PL3765489T3 (pl) 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
MX2020010028A (es) 2018-03-29 2020-10-14 Genentech Inc Actividad lactogenica modulada en celulas de mamifero.
EP3774917B1 (en) 2018-03-30 2025-10-29 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against lag-3 and uses thereof
JP7104458B2 (ja) 2018-04-02 2022-07-21 上海博威生物医薬有限公司 リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
EP3773656A1 (en) 2018-04-09 2021-02-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
SG11202009804RA (en) 2018-04-11 2020-11-27 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3774900A1 (en) 2018-04-13 2021-02-17 F. Hoffmann-La Roche AG Her2-targeting antigen binding molecules comprising 4-1bbl
TWI851572B (zh) 2018-04-18 2024-08-11 美商山可爾股份有限公司 IL-15/IL-15Rα異二聚體Fc融合蛋白及其用途
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
JP7366056B2 (ja) 2018-04-18 2023-10-20 ゼンコア インコーポレイテッド ＩＬ－１５／ＩＬ－１５ＲＡ Ｆｃ融合タンパク質およびＬＡＧ－３抗原結合ドメインを含む、ＬＡＧ－３を標的とするヘテロ二量体融合タンパク質
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
SG11202010601VA (en) 2018-05-03 2020-11-27 Genmab Bv Antibody variant combinations and uses thereof
WO2019219721A1 (en) 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Targeted intracellular delivery of large nucleic acids
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
TW202003580A (zh) 2018-05-21 2020-01-16 美商坎伯斯治療有限責任公司 用於增強nk細胞對標靶細胞之殺死之組合物及方法
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
MX2020013443A (es) 2018-06-13 2021-02-26 Novartis Ag Receptores de antigeno quimerico de bcma y usos de los mismos.
CN112469440B (zh) 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
JP7472119B2 (ja) 2018-06-19 2024-04-22 アターガ，エルエルシー 補体第５成分に対する抗体分子およびその使用
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
MA53015A (fr) 2018-06-29 2021-05-05 Alector Llc Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
JP2021528988A (ja) 2018-07-04 2021-10-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3820890A1 (en) 2018-07-13 2021-05-19 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
KR102530517B1 (ko) 2018-07-13 2023-05-09 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법
CN120865412A (zh) 2018-07-13 2025-10-31 根马布股份公司 Cd38抗体变体及其用途
EP3823673A4 (en) 2018-07-20 2022-05-11 Surface Oncology, Inc. Anti-cd112r compositions and methods
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
AU2019315226B2 (en) 2018-08-03 2025-09-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EP3608674A1 (en) 2018-08-09 2020-02-12 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
CN118754986A (zh) 2018-08-10 2024-10-11 中外制药株式会社 抗cd137抗原结合分子及其应用
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US20210188957A1 (en) 2018-08-29 2021-06-24 Chugai Seiyaku Kabushiki Kaisha Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3111458A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
US11573226B2 (en) 2018-09-10 2023-02-07 Genentech, Inc. Systems and methods for affinity capillary electrophoresis
EP4660623A2 (en) 2018-09-10 2025-12-10 Genentech Inc. Systems and methods for affinity capillary electrophoresis
EP3853611A1 (en) 2018-09-19 2021-07-28 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for bladder cancer
CA3155293A1 (en) 2018-09-24 2020-04-02 The Medical College Of Wisconsin, Inc. System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
JP2022511396A (ja) 2018-10-01 2022-01-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
WO2020070041A1 (en) 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-fap clone 212
MA53822A (fr) 2018-10-03 2021-08-11 Xencor Inc Protéines de fusion fc hétérodimères d'il -12
JP7522106B2 (ja) 2018-10-04 2024-07-24 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体を含む医薬組成物
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
JP7453219B2 (ja) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド Ｐｄ－１単一ドメイン抗体およびその治療用組成物
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
US20230124851A1 (en) 2018-10-11 2023-04-20 Inhibrx, lnc. B7h3 single domain antibodies and therapeutic compositions thereof
PE20211055A1 (es) 2018-10-12 2021-06-07 Xencor Inc Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
EP3870598A1 (en) 2018-10-23 2021-09-01 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
TW202037381A (zh) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 綴合化學降解誘導劑及使用方法
WO2020089051A1 (en) 2018-10-29 2020-05-07 F. Hoffmann-La Roche Ag Antibody formulation
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020094744A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
TWI840442B (zh) 2018-11-13 2024-05-01 美商坎伯斯治療有限責任公司 對抗檢查點分子之多特異性結合構築體及其用途
WO2020104496A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020115115A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
EP3898667A2 (en) 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Modified antibody fcs and methods of use
JP2022514280A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー Ｍｄｍ２阻害剤のための延長低用量レジメン
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
MY198034A (en) 2018-12-21 2023-07-27 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules
SG11202106100VA (en) 2018-12-21 2021-07-29 23Andme Inc Anti-il-36 antibodies and methods of use thereof
BR112021011939A2 (pt) 2018-12-21 2021-09-14 F. Hoffmann-La Roche Ag Anticorpo que se liga a cd3, anticorpos que se ligam a cd3 e tyrp-1, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo que se liga a cd3, composição farmacêutica e usos do anticorpo
US20200223925A1 (en) 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
CN113795508A (zh) 2018-12-24 2021-12-14 赛诺菲 具有突变型Fab结构域的多特异性结合蛋白
AU2019416895A1 (en) 2018-12-24 2021-08-12 Sanofi Pseudofab-based multispecific binding proteins
US20220073630A1 (en) 2018-12-28 2022-03-10 Hoffmann-La Roche, Inc. A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
JP7241888B2 (ja) 2018-12-30 2023-03-17 エフ． ホフマン－ラ ロシュ アーゲー ｐＨ勾配ＳＰＲに基づく結合アッセイ
SG11202106686PA (en) 2019-01-04 2021-07-29 Resolve Therapeutics Llc Treatment of sjogren's disease with nuclease fusion proteins
AU2020205965A1 (en) * 2019-01-07 2021-07-01 Shattuck Labs. Inc. Heterodimeric proteins for modulating gamma delta T cells
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
PH12021551676A1 (en) 2019-01-18 2022-03-07 Janssen Biotech Inc Gprc5d chimeric antigen receptors and cells expressing the same
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
GB2599227B (en) 2019-02-21 2024-05-01 Marengo Therapeutics Inc Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
EP3927371A1 (en) 2019-02-22 2021-12-29 Novartis AG Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020174370A2 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
BR112021016955A2 (pt) 2019-03-01 2021-11-23 Xencor Inc Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
EP3969476A1 (en) 2019-03-04 2022-03-23 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
AU2020238811A1 (en) 2019-03-08 2021-07-22 Genentech, Inc. Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
KR20210141555A (ko) 2019-03-14 2021-11-23 제넨테크, 인크. Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
CN113646622B (zh) 2019-03-29 2024-11-12 豪夫迈·罗氏有限公司 用于多价分子的功能分析的基于spr的结合测定
EP3947440A1 (en) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Method for generating avid-binding multispecific antibodies
SG11202110732XA (en) 2019-03-29 2021-10-28 Atarga Llc Anti fgf23 antibody
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
CA3134522A1 (en) 2019-04-19 2020-10-22 Genentech, Inc. Anti-mertk antibodies and their methods of use
TW202106714A (zh) 2019-04-25 2021-02-16 瑞士商赫孚孟拉羅股份公司 藉由多肽鏈交換製造抗體衍生之多肽
KR20220004062A (ko) 2019-04-25 2022-01-11 에프. 호프만-라 로슈 아게 반감기가 연장된 활성화 가능한 치료용 다중특이적 폴리펩티드
JP7688584B2 (ja) 2019-04-25 2025-06-04 エフ． ホフマン－ラ ロシュ アーゲー ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
AU2020268896B2 (en) 2019-05-03 2024-11-28 F. Hoffmann-La Roche Ag Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
JP2022531894A (ja) 2019-05-09 2022-07-12 ゲンマブ ビー．ブイ． がんの処置において使用するための抗ｄｒ５抗体の組み合わせの投与レジメン
AR122263A1 (es) 2019-05-09 2022-08-31 Genentech Inc Métodos para producir anticuerpos
CN119470884A (zh) 2019-05-13 2025-02-18 豪夫迈·罗氏有限公司 抑制干扰的药代动力学免疫测定
TW202108178A (zh) 2019-05-14 2021-03-01 美商建南德克公司 使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
CN114173810B (zh) 2019-05-21 2024-09-06 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
CR20210576A (es) 2019-05-21 2021-12-15 Novartis Ag Moléculas de unión a cd19 y usos de las mismas
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
EP3981429A4 (en) 2019-06-10 2023-07-26 Chugai Seiyaku Kabushiki Kaisha Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
US20200392229A1 (en) 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
AU2020294879A1 (en) 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CA3140323A1 (en) 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
AU2020294880B2 (en) 2019-06-19 2024-05-02 F. Hoffmann-La Roche Ag Method for the generation of a protein expressing cell by targeted integration using Cre mRNA
EP3986925A1 (en) 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
BR112021025436A2 (pt) 2019-06-19 2022-02-01 Hoffmann La Roche Métodos para produzir um anticorpo biespecífico trivalente, biespecífico bivalente, biespecífico multivalente, para produzir uma célula de mamífero recombinante e para produzir um anticorpo trivalente, ácidos desoxirribonucleicos, usos de um ácido desoxirribonucleico, células de mamífero recombinante, composições e uso de mrna de recombinase cre
CA3141378A1 (en) 2019-06-26 2020-12-30 F. Hoffmann-La Roche Ag Fusion of an antibody binding cea and 4-1bbl
AU2020306672B2 (en) 2019-06-26 2023-08-24 F. Hoffmann-La Roche Ag Mammalian cell lines with SIRT-1 gene knockout
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
CA3143524A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
EP3994169A1 (en) 2019-07-02 2022-05-11 F. Hoffmann-La Roche AG Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
EP3999532A2 (en) 2019-07-16 2022-05-25 Sanofi Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
CN114174338A (zh) 2019-07-31 2022-03-11 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
TW202519558A (zh) 2019-07-31 2025-05-16 美商阿列克特有限責任公司 抗ms4a4a抗體及其使用方法
BR112022001460A2 (pt) 2019-07-31 2022-03-22 Hoffmann La Roche Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
CA3148740A1 (en) 2019-08-06 2021-02-11 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
TW202120556A (zh) 2019-08-08 2021-06-01 美商再生元醫藥公司 新穎抗原結合分子型式
CR20220111A (es) 2019-08-13 2022-05-04 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras referencia cruzada a solicitudes relacionadas
WO2021046133A1 (en) 2019-09-03 2021-03-11 Amgen Inc. Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
JP2022547577A (ja) 2019-09-12 2022-11-14 ジェネンテック， インコーポレイテッド ループス腎炎を治療する組成物及び方法
CN114423791B (zh) 2019-09-18 2026-01-09 豪夫迈·罗氏有限公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
TW202126699A (zh) 2019-09-20 2021-07-16 美商建南德克公司 用於抗類胰蛋白酶抗體之投藥
CN114829401A (zh) 2019-09-27 2022-07-29 南京金斯瑞生物科技有限公司 抗vhh域抗体及其用途
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
EP4045090A1 (en) 2019-10-18 2022-08-24 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
KR20220103947A (ko) 2019-10-21 2022-07-25 노파르티스 아게 베네토클락스 및 tim-3 억제제를 사용한 조합 요법
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
US12240907B2 (en) 2019-11-05 2025-03-04 Regeneron Pharmaceuticals, Inc. N-terminal scFv multispecific binding molecules
WO2021089850A1 (en) 2019-11-06 2021-05-14 Genmab B.V. Antibody variant combinations and uses thereof
US20220389119A1 (en) 2019-11-08 2022-12-08 Amgen Inc. ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
US20220396839A1 (en) 2019-11-12 2022-12-15 Foundation Medicine, Inc. Methods of detecting a fusion gene encoding a neoantigen
BR112022008172A2 (pt) 2019-11-15 2022-07-12 Hoffmann La Roche Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica
KR20220114560A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 항-cd79 키메라 항원 수용체, car-t 세포 및 이의 용도
JP2023501717A (ja) 2019-11-19 2023-01-18 アムジエン・インコーポレーテツド 新規の多重特異性抗体フォーマット
CA3163104A1 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
CN113135996A (zh) 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
BR112022009723A2 (pt) 2019-12-17 2022-08-09 Pfizer Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
BR112022011949A2 (pt) 2019-12-17 2022-11-22 Amgen Inc Dupla de interleucina-2/agonista do receptor tnf para uso em terapia
US11739142B2 (en) 2019-12-18 2023-08-29 Hoffmann-La Roche Inc. Bispecific anti-CCL2 antibodies
US11987632B2 (en) 2019-12-18 2024-05-21 Hoffmann-La Roche Inc. Antibodies binding to HLA-A2/MAGE-A4
JP7751581B2 (ja) 2019-12-20 2025-10-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｉｌ－３７融合タンパク質及びその使用
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之ｉｌ２促效劑及其使用方法（二）
PH12022551496A1 (en) 2019-12-23 2023-12-11 Genentech Inc Apolipoprotein l1-specific antibodies and methods of use
UA128549C2 (uk) 2019-12-27 2024-08-07 Чугаі Сейяку Кабусікі Кайся Антитіло до ctla-4 та його застосування
TWI766512B (zh) 2020-01-02 2022-06-01 瑞士商赫孚孟拉羅股份公司 用於判定腦中的治療性抗體量之方法
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2021206523A1 (en) 2020-01-09 2022-05-26 F. Hoffmann-La Roche Ag New 4-1BBL trimer-containing antigen binding molecules
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021144422A1 (en) 2020-01-15 2021-07-22 F. Hoffmann-La Roche Ag Methods to decrease impurities from recombinant protein manufacturing processes
BR112022013553A2 (pt) 2020-01-16 2022-09-06 Genmab As Composição farmacêutica, anticorpo, e, método para tratar uma doença
WO2021146636A1 (en) 2020-01-17 2021-07-22 Becton, Dickinson And Company Methods and compositions for single cell secretomics
AU2021207348A1 (en) 2020-01-17 2022-08-11 Novartis Ag Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
BR112022014667A2 (pt) 2020-01-29 2022-09-20 Inhibrx Inc Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
AU2021218927B2 (en) 2020-02-10 2024-12-19 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
AU2021220887B2 (en) 2020-02-10 2024-11-21 Shanghai Escugen Biotechnology Co., Ltd. CLDN18.2 antibody and use thereof
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
AU2021226582A1 (en) 2020-02-26 2022-10-13 Biograph 55, Inc. C19 C38 bispecific antibodies
WO2021173844A1 (en) 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies
EP4110377A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN115298221A (zh) 2020-03-18 2022-11-04 健玛保 结合b7h4的抗体
TW202535930A (zh) 2020-03-19 2025-09-16 美商建南德克公司 同功型選擇性抗-TGF-β 抗體及其使用方法
PE20230414A1 (es) 2020-03-24 2023-03-07 Genentech Inc Agentes de fijacion a tie2 y metodos de uso
MX2022011847A (es) 2020-03-25 2023-01-04 Lilly Co Eli Proteínas de unión multiespecíficas y métodos para desarrollarlas.
US12098365B2 (en) 2020-03-26 2024-09-24 Genentech, Inc. Modified mammalian cells
JP2023520773A (ja) 2020-03-27 2023-05-19 ノバルティス アーゲー 増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療
IL296514A (en) 2020-03-30 2022-11-01 Univ Mie Bispecific antibody
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
US20240183826A9 (en) 2020-04-02 2024-06-06 Chugai Seiyaku Kabushiki Kaisha Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CR20220512A (es) 2020-04-15 2022-11-07 Hoffmann La Roche Inmunoconjugados
KR20230020394A (ko) 2020-04-15 2023-02-10 보이저 테라퓨틱스, 인크. Tau 결합 화합물
BR112022021441A2 (pt) 2020-04-24 2022-12-13 Genentech Inc Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
JP2023523011A (ja) 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
JP2023522417A (ja) 2020-04-24 2023-05-30 エフ． ホフマン－ラ ロシュ アーゲー スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
JP2023523450A (ja) 2020-04-28 2023-06-05 ジェネンテック， インコーポレイテッド 非小細胞肺がん免疫療法のための方法及び組成物
CA3180173A1 (en) 2020-04-30 2021-11-04 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
JP2023527962A (ja) 2020-05-03 2023-07-03 レヴィーナ （スジョウ） バイオファーマ カンパニー， リミテッド 抗ｔｒｏｐ２抗体を含む抗体薬物複合体（ａｄｃ）、かかるａｄｃを含む組成物、ならびにそれらを作製および使用する方法
BR112022021884A2 (pt) 2020-05-06 2022-12-20 Dragonfly Therapeutics Inc Proteínas que se ligam a nkg2d, cd16 e clec12a
US12435154B2 (en) 2020-05-08 2025-10-07 Genmab A/S Bispecific antibodies against CD3 and CD20
US20230181712A1 (en) 2020-05-11 2023-06-15 Hoffmann-La Roche Inc. Combination therapy with modified pbmcs and an immunoconjugate
EP4149963A1 (en) 2020-05-12 2023-03-22 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
JP2023520249A (ja) 2020-05-15 2023-05-16 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液中の可視粒子形成の防止方法
US20230192797A1 (en) 2020-05-18 2023-06-22 Jiangsu Simcere Pharmaceutical Co., Ltd. Human il-15 mutant and uses thereof
CN115605185A (zh) 2020-05-19 2023-01-13 豪夫迈·罗氏有限公司（Ch） 螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
US12146000B2 (en) 2020-05-19 2024-11-19 Boehringer Ingelheim International Gmbh Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer
KR20230018425A (ko) 2020-05-29 2023-02-07 23앤드미 인코포레이티드 항-cd200r1 항체 및 이의 사용 방법
CN115697489A (zh) 2020-06-08 2023-02-03 豪夫迈·罗氏有限公司 抗hbv抗体及其使用方法
CN115698719A (zh) 2020-06-12 2023-02-03 基因泰克公司 用于癌症免疫疗法的方法和组合物
KR20230152789A (ko) 2020-06-19 2023-11-03 추가이 세이야쿠 가부시키가이샤 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
MX2022015890A (es) 2020-06-19 2023-01-24 Hoffmann La Roche Anticuerpos biespecificos para linfocitos t activados por proteasa.
CR20220628A (es) 2020-06-19 2023-01-24 Hoffmann La Roche Anticuerpos que se unen a cd3
CR20220639A (es) 2020-06-19 2023-02-17 Hoffmann La Roche Anticuerpos que se unen a cd3 y folr1
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
MX2022015203A (es) 2020-06-19 2023-01-05 Hoffmann La Roche Moleculas de union al dominio fc de activacion inmunitaria.
BR112022025856A2 (pt) 2020-06-19 2023-01-10 Hoffmann La Roche Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
EP4168443A1 (en) 2020-06-22 2023-04-26 Almirall S.A. Anti-il-36 antibodies and methods of use thereof
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
IL297880A (en) 2020-06-23 2023-01-01 Hoffmann La Roche Agonistic cd28 antigen binding molecules targeting her2
IL299161A (en) 2020-06-24 2023-02-01 Genentech Inc Cell lines resistant to apoptosis
JP2023531067A (ja) 2020-06-25 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022008468A1 (en) 2020-07-07 2022-01-13 F. Hoffmann-La Roche Ag Alternative surfactants as stabilizers for therapeutic protein formulations
JP2023533533A (ja) 2020-07-10 2023-08-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、当該細胞に対して放射性ヌクレオチドを標的化する抗体
CR20230009A (es) 2020-07-16 2023-01-25 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
CN116490518A (zh) 2020-07-17 2023-07-25 西穆尔克斯股份有限公司 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
BR112023000839A2 (pt) 2020-07-17 2023-02-07 Genentech Inc Anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos para produzir um anticorpo que se liga a notch2 humano, para tratar um indivíduo com uma doença pulmonar muco-obstrutiva e para reduzir o número de células secretoras em um indivíduo, composição farmacêutica, anticorpo, anticorpo para uso e uso do anticorpo
IL299860A (en) 2020-07-21 2023-03-01 Genentech Inc Antibody-conjugated chemical factors for the discharge of BRM and their methods
EP4185388A1 (en) 2020-07-23 2023-05-31 Genmab B.V. A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
US20230322898A1 (en) 2020-07-31 2023-10-12 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising cell expressing chimeric receptor
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP4192859A1 (en) 2020-08-06 2023-06-14 BioNTech SE Binding agents for coronavirus s protein
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
WO2022044248A1 (ja) 2020-08-28 2022-03-03 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4208200A2 (en) 2020-09-02 2023-07-12 Genmab A/S Antibody therapy
JP2023541858A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
KR20230066391A (ko) 2020-09-10 2023-05-15 젠맵 에이/에스 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
MX2023002540A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular.
CN116782933A (zh) 2020-09-10 2023-09-19 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
MX2023002541A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes.
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
TW202227496A (zh) 2020-09-14 2022-07-16 瑞士商伊克諾斯科學公司 結合至ｉｌ１ｒａｐ之抗體及其用途
AU2021342566A1 (en) 2020-09-21 2023-03-02 Genentech, Inc. Purification of multispecific antibodies
AU2021347580A1 (en) 2020-09-24 2023-04-06 F. Hoffmann-La Roche Ag Mammalian cell lines with gene knockout
EP4221742A1 (en) 2020-10-02 2023-08-09 Genmab A/S Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
EP4674480A2 (en) 2020-10-02 2026-01-07 Keros Therapeutics, Inc. Methods of using activin receptor type ii variants
TWI836278B (zh) 2020-10-05 2024-03-21 美商建南德克公司 用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
AR123767A1 (es) 2020-10-13 2023-01-11 Janssen Biotech Inc Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
TW202233671A (zh) 2020-10-20 2022-09-01 美商建南德克公司 Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
AU2021363536A1 (en) 2020-10-20 2023-02-23 F. Hoffmann-La Roche Ag Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
CN116829586A (zh) 2020-10-21 2023-09-29 勃林格殷格翰国际有限公司 用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子
UY39488A (es) 2020-10-28 2022-04-29 Janssen Biotech Inc Composiciones y métodos para modular la inmunidad mediada por la cadena delta gamma
TW202233677A (zh) 2020-11-02 2022-09-01 新加坡商蜂鳥生物科技私人有限公司 Bcma/taci抗原結合分子
US20250215081A1 (en) 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
US20240010748A1 (en) 2020-11-10 2024-01-11 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
IL302700A (en) 2020-11-13 2023-07-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
JP2023549316A (ja) 2020-11-16 2023-11-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法
EP4244248A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Fab high mannose glycoforms
KR20230117167A (ko) 2020-12-02 2023-08-07 상하이 헨리우스 바이오테크, 인크. 항GARP/TGFβ항체 및 사용 방법
CA3202986A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
CN116635403A (zh) 2020-12-04 2023-08-22 豪夫迈·罗氏有限公司 pH依赖性突变型白细胞介素-2多肽
IL303294A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Antibodies against interleukin-22
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
WO2022129120A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
CN116601175A (zh) 2020-12-18 2023-08-15 豪夫迈·罗氏有限公司 用于靶向疗法的前体蛋白和试剂盒
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
AU2022206061A1 (en) 2021-01-06 2023-07-06 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
US20240082437A1 (en) 2021-01-12 2024-03-14 Hoffmann-La Roche Inc. Split antibodies which bind to cancer cells and target radionuclides to said cells
MX2023008083A (es) 2021-01-13 2023-07-13 Hoffmann La Roche Tratamiento conjunto.
WO2022162587A1 (en) 2021-01-27 2022-08-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
WO2022169872A1 (en) 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
EP4294430A1 (en) 2021-02-16 2023-12-27 Janssen Biotech, Inc. Materials and methods for enhanced linker targeting
WO2022175217A1 (en) 2021-02-18 2022-08-25 F. Hoffmann-La Roche Ag Method for resolving complex, multistep antibody interactions
MX2023009717A (es) 2021-02-19 2024-01-08 Shaperon Inc Anticuerpo de dominio individual contra cúmulo de diferenciación 47 (cd47) y uso del mismo.
JP7773238B2 (ja) 2021-02-19 2025-11-19 シャペロン インク． Ｐｄ－ｌ１に対する単一ドメイン抗体及びその用途
US20240181073A1 (en) 2021-03-03 2024-06-06 Sorrento Therapeutics, Inc. Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US20240092856A1 (en) 2021-03-09 2024-03-21 Hoffmann-La Roche Inc. Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
EP4304724A1 (en) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
CN117062839A (zh) 2021-03-12 2023-11-14 基因泰克公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
WO2022189667A1 (en) 2021-03-12 2022-09-15 Genmab A/S Non-activating antibody variants
WO2022198192A1 (en) 2021-03-15 2022-09-22 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2022197947A1 (en) 2021-03-18 2022-09-22 Alector Llc Anti-tmem106b antibodies and methods of use thereof
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
EP4314063A1 (en) 2021-03-23 2024-02-07 Alector LLC Anti-tmem106b antibodies for treating and preventing coronavirus infections
AR125210A1 (es) 2021-03-24 2023-06-21 Janssen Biotech Inc Anticuerpos dirigidos a cd22 y cd79b
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
TW202304990A (zh) 2021-03-26 2023-02-01 美商健生生物科技公司 針對成對螺旋絲ｔａｕ之人源化抗體及其用途
WO2022210485A1 (ja) 2021-03-29 2022-10-06 第一三共株式会社 安定な多重特異性分子及びその利用
US20240301031A1 (en) 2021-03-31 2024-09-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Truncated taci polypeptide and fusion protein and use thereof
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
EP4320444A1 (en) 2021-04-09 2024-02-14 F. Hoffmann-La Roche AG Process for selecting cell clones expressing a heterologous polypeptide
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
IL307501A (en) 2021-04-19 2023-12-01 Hoffmann La Roche Modified mammalian cells
AU2022262644A1 (en) 2021-04-23 2023-11-09 Genmab A/S Anti-cd70 antibodies, conjugates thereof and methods of using the same
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
KR20240005722A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약
BR112023022844A2 (pt) 2021-05-03 2024-01-23 UCB Biopharma SRL Anticorpos
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
MX2023012974A (es) 2021-05-04 2023-11-15 Regeneron Pharma Agonistas multiespecificos de receptores del fgf21 y sus usos.
US20240383982A1 (en) 2021-05-07 2024-11-21 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
WO2022238481A1 (en) 2021-05-11 2022-11-17 Modiquest B.V. Antibodies
KR20240006586A (ko) 2021-05-12 2024-01-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
JP2024520901A (ja) 2021-05-12 2024-05-27 ジェネンテック， インコーポレイテッド びまん性大細胞型ｂ細胞リンパ腫を治療するための抗ｃｄ７９ｂイムノコンジュゲートを使用する方法
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
AU2022273737A1 (en) 2021-05-14 2023-11-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
EP4341385A1 (en) 2021-05-21 2024-03-27 Genentech, Inc. Modified cells for the production of a recombinant product of interest
CN113278071B (zh) 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4155321A1 (en) 2021-06-04 2023-03-29 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
AU2022288574A1 (en) 2021-06-09 2023-11-30 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
AU2022289684A1 (en) 2021-06-09 2023-10-05 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
MX2023014647A (es) 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
US20240279341A1 (en) 2021-06-16 2024-08-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
AR126161A1 (es) 2021-06-17 2023-09-27 Boehringer Lngelheim Int Gmbh Moléculas de fijación triespecíficas novedosas
WO2022263638A1 (en) 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
KR20240021859A (ko) 2021-06-18 2024-02-19 에프. 호프만-라 로슈 아게 이중특이적 항-ccl2 항체
WO2022268740A1 (en) 2021-06-21 2022-12-29 Genmab A/S Combination dosage regime of cd137 and pd-l1 binding agents
EP4359436A1 (en) 2021-06-22 2024-05-01 Novartis AG Bispecific antibodies for use in treatment of hidradenitis suppurativa
WO2022272128A1 (en) 2021-06-24 2022-12-29 Erasca, Inc. Antibodies against egfr and their uses
MX2023013897A (es) 2021-06-25 2023-12-11 Chugai Pharmaceutical Co Ltd Anticuerpo anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4).
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
CN119838007A (zh) 2021-06-25 2025-04-18 中外制药株式会社 抗ctla-4抗体的用途
CN117580865A (zh) 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用
KR20240028452A (ko) 2021-07-02 2024-03-05 제넨테크, 인크. 암을 치료하기 위한 방법 및 조성물
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023281120A1 (en) 2021-07-09 2023-01-12 Luxembourg Institute Of Health (Lih) Dimeric protein complexes and uses thereof
KR20240032930A (ko) 2021-07-13 2024-03-12 제넨테크, 인크. 사이토카인 방출 증후군을 예측하기 위한 다변량 모델
WO2023284829A1 (zh) 2021-07-14 2023-01-19 江苏恒瑞医药股份有限公司 特异性结合hgfr和egfr的抗原结合分子及其医药用途
KR20240032889A (ko) 2021-07-14 2024-03-12 제넨테크, 인크. 항-c-c 모티프 케모카인 수용체 8(ccr8) 항체 및 사용 방법
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2023001884A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
EP4373576A1 (en) 2021-07-22 2024-05-29 Genentech, Inc. Brain targeting compositions and methods of use thereof
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
KR20240038008A (ko) 2021-07-28 2024-03-22 에프. 호프만-라 로슈 아게 암 치료 방법 및 조성물
EP4380980A1 (en) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use
EP4384553A1 (en) 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies
WO2023022965A2 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
CN118284623A (zh) 2021-08-23 2024-07-02 伊莫尼塔斯治疗公司 抗cd161抗体及其用途
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
JP2024534853A (ja) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド 抗ポリビキチン多重特異性抗体
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
AU2022338208A1 (en) 2021-09-06 2024-03-21 Genmab A/S Antibodies capable of binding to cd27, variants thereof and uses thereof
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN117813323A (zh) 2021-09-23 2024-04-02 江苏恒瑞医药股份有限公司 抗klb抗体及用途
CN118562018B (zh) * 2021-09-30 2024-12-13 宁波三生生物科技股份有限公司 重组促卵泡激素融合蛋白
KR20240067099A (ko) 2021-09-30 2024-05-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il23 항체 융합 단백질 및 용도
WO2023057571A1 (en) 2021-10-08 2023-04-13 Genmab A/S Antibodies binding to cd30 and cd3
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
JP2024537096A (ja) 2021-10-14 2024-10-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための代替的なＰＤ１－ＩＬ７ｖイムノコンジュゲート
JP7793774B2 (ja) 2021-10-14 2026-01-05 テネオバイオ， インコーポレイテッド メソテリン結合タンパク質及びその使用
IL312005A (en) 2021-10-14 2024-06-01 Hoffmann La Roche New interleukin-7 immunoconjugates
WO2023064947A1 (en) 2021-10-15 2023-04-20 Regenxbio Inc. Antibodies and methods of using thereof
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023073599A1 (en) 2021-10-28 2023-05-04 Novartis Ag Engineered fc variants
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US20230279153A1 (en) 2021-11-11 2023-09-07 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023094282A1 (en) 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Quantification of low amounts of antibody sideproducts
JP2024543257A (ja) 2021-11-26 2024-11-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
MX2024006387A (es) 2021-12-01 2024-06-04 Chugai Pharmaceutical Co Ltd Metodo para preparar formulacion que contiene anticuerpo.
WO2023098846A1 (zh) 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
JP2024547020A (ja) 2021-12-17 2024-12-26 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体、多重特異性抗体及びその使用方法
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
EP4416301B1 (en) 2021-12-21 2025-06-11 F. Hoffmann-La Roche AG Method for the determination of hydrolytic activity
CA3240378A1 (en) 2021-12-23 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody
EP4458854A1 (en) 2021-12-31 2024-11-06 Shandong Simcere Biopharmaceutical Co., Ltd. Gprc5d antibody and application thereof
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗ｎｏｔｃｈ２抗體及結合物及其使用方法
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
MX2024008833A (es) 2022-01-28 2024-07-25 Genmab As Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes.
EP4469083A1 (en) 2022-01-28 2024-12-04 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN118574855A (zh) 2022-02-07 2024-08-30 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
JP2025508692A (ja) 2022-02-11 2025-04-10 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 免疫複合体及びその使用
JP7654346B2 (ja) 2022-03-03 2025-04-01 ファイザー・インク 多重特異性抗体およびその使用
CN119173278A (zh) 2022-03-10 2024-12-20 维硕公司 抗体偶联药物及其用途
IL315544A (en) 2022-03-11 2024-11-01 Janssen Pharmaceutica Nv Multispecific antibodies and their uses
CA3254098A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv MULTISPECIFIC ANTIBODIES AND THEIR USES
AU2023232448A1 (en) 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
JP2025508160A (ja) 2022-03-14 2025-03-21 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｇｐｒｃ５ｄとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
TW202400232A (zh) 2022-03-16 2024-01-01 日商第一三共股份有限公司 多特異性分子與免疫檢查點抑制劑之組合
AU2023236386A1 (en) 2022-03-18 2024-10-10 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
AU2023238766A1 (en) 2022-03-23 2024-07-25 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
AR128876A1 (es) 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
AU2022450448A1 (en) 2022-04-01 2024-10-10 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP7701982B2 (ja) 2022-04-13 2025-07-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法
AU2023253705A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of therapeutic proteins and methods of use
US20250304689A1 (en) 2022-04-13 2025-10-02 Genmab A/S Bispecific antibodies against cd3 and cd20
JP2025513335A (ja) 2022-04-19 2025-04-24 エフ． ホフマン－ラ ロシュ アーゲー 改良された産生細胞
CA3249779A1 (en) 2022-04-26 2025-06-17 Chugai Seiyaku Kabushiki Kaisha SYRINGE WITH A FILTER CONTAINING A PHARMACEUTICAL PREPARATION
AU2023259761A1 (en) 2022-04-26 2024-09-26 Novartis Ag Multispecific antibodies targeting il-13 and il-18
JP2025517612A (ja) 2022-05-03 2025-06-10 ジェネンテック， インコーポレイテッド 抗Ｌｙ６Ｅ抗体、免疫コンジュゲートおよびその使用
EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof
US20250340668A1 (en) 2022-05-11 2025-11-06 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
EP4522275A1 (en) 2022-05-12 2025-03-19 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
TW202413412A (zh) 2022-05-12 2024-04-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
EP4522757A2 (en) 2022-05-13 2025-03-19 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3257348A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. INTERLEUKIN-2 PROPROTEINS AND THEIR USES
JP2025517572A (ja) 2022-06-03 2025-06-05 エフ． ホフマン－ラ ロシュ アーゲー 改良された産生細胞
KR20250035049A (ko) 2022-06-04 2025-03-11 리제너론 파아마슈티컬스, 인크. 인터루킨-2 프로프로테인 및 이의 용도
CN119317648A (zh) 2022-06-06 2025-01-14 山东先声生物制药有限公司 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
CN119256017A (zh) 2022-06-23 2025-01-03 江苏恒瑞医药股份有限公司 特异性结合dll3和cd3的抗原结合分子及其医药用途
CA3261147A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
IL317689A (en) 2022-07-15 2025-02-01 Boehringer Ingelheim Int Binding molecules for cancer treatment
JP2025523845A (ja) 2022-07-19 2025-07-25 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
JP2025523995A (ja) 2022-07-22 2025-07-25 ジェネンテック， インコーポレイテッド 抗ｓｔｅａｐ１抗原結合分子およびその使用
US20240228664A9 (en) 2022-07-22 2024-07-11 Bristol-Myers Squibb Company Antibodies Binding to Human PAD4 and Uses Thereof
AU2023312905A1 (en) 2022-07-27 2025-01-16 Teneobio, Inc. Mesothelin binding proteins and uses thereof
CA3261511A1 (en) 2022-07-29 2024-02-01 Alector Llc CD98HC ANTIGEN BINDING DOMAINS AND THEIR USES
IL317876A (en) 2022-07-29 2025-02-01 Alector Llc Transferrin receptor antigen binding domains and their uses
CN120603847A (zh) 2022-08-03 2025-09-05 辉瑞公司 抗il27r抗体及其使用方法
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
AU2023320453A1 (en) 2022-08-03 2025-02-06 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
EP4566673A1 (en) 2022-08-05 2025-06-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule specifically binding to gucy2c and cd3 and pharmaceutical use thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN120051483A (zh) 2022-08-18 2025-05-27 再生元制药公司 干扰素前蛋白及其用途
JP2025531738A (ja) 2022-09-01 2025-09-25 ジェネンテック， インコーポレイテッド 膀胱がんの治療方法及び診断方法
WO2024052922A1 (en) 2022-09-11 2024-03-14 Yeda Research And Development Co. Ltd. Anti-klk4 antibodies and uses thereof
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
IL319570A (en) 2022-09-15 2025-05-01 Avidicure Ip B V Multispecific antigen-binding proteins for targeting NK cells to tumors and their uses
EP4594353A1 (en) 2022-09-28 2025-08-06 F. Hoffmann-La Roche AG Improved protease-activatable t cell bispecific antibodies
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
CN120019277A (zh) 2022-10-12 2025-05-16 豪夫迈·罗氏有限公司 用于对细胞进行分类的方法
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN115724975A (zh) 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
US20250382378A1 (en) 2022-10-31 2025-12-18 Genmab A/S Cd38 antibodies and uses thereof
KR20250096769A (ko) 2022-11-01 2025-06-27 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 글리피칸-3에 대한 이중특이성 항체 및 이의 용도
US20240174761A1 (en) 2022-11-02 2024-05-30 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
JP2025537197A (ja) 2022-11-08 2025-11-14 ジェネンテック， インコーポレイテッド 小児期発症特発性ネフローゼ症候群を治療するための組成物および方法
KR20250134582A (ko) 2022-11-10 2025-09-11 이뮤비아 인코포레이티드 Dr5 및 muc16에 결합하는 세포독성 이중특이성 항체 및 이의 용도
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
EP4619428A1 (en) 2022-11-15 2025-09-24 F. Hoffmann-La Roche AG Antigen binding molecules
JP2025537782A (ja) 2022-11-15 2025-11-20 エフ． ホフマン－ラ ロシュ アーゲー 活性化可能なエフェクタードメインを有する組換え結合タンパク質
CN120417937A (zh) 2022-11-17 2025-08-01 赛诺菲 Ceacam5抗体-药物缀合物及其使用方法
EP4623086A1 (en) 2022-11-23 2025-10-01 F. Hoffmann-La Roche AG Method for increasing recombinant protein expression
CN120265651A (zh) 2022-11-25 2025-07-04 中外制药株式会社 用于生产蛋白质的方法
EP4628507A1 (en) 2022-11-29 2025-10-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Cldn18.2/4-1bb binding protein and medical use thereof
WO2024120517A1 (zh) 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
JP2025538819A (ja) 2022-12-12 2025-11-28 ジェネンテック， インコーポレイテッド ポリペプチドシアル酸含有量の最適化
EP4385999A1 (en) 2022-12-14 2024-06-19 ModiQuest B.V. Antibodies
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
KR20250134733A (ko) 2022-12-16 2025-09-11 리제너론 파아마슈티컬스, 인크. Aav 입자에 결합하는 항원-결합 분자 및 용도
WO2024138191A1 (en) 2022-12-23 2024-06-27 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof
WO2024151978A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
IL322053A (en) 2023-01-13 2025-09-01 Regeneron Pharma FGFR3 binding molecules and methods of using them
AR131638A1 (es) 2023-01-18 2025-04-16 Genentech Inc Anticuerpos multiespecíficos y usos de estos
AR131635A1 (es) 2023-01-20 2025-04-16 Hoffmann La Roche Inmunoconjugados
CN120569410A (zh) 2023-01-25 2025-08-29 豪夫迈·罗氏有限公司 与csf1r和cd3结合的抗体
EP4655315A1 (en) 2023-01-25 2025-12-03 F. Hoffmann-La Roche AG Payload-bearing multispecific antibodies
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
TW202436339A (zh) 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024165454A1 (en) 2023-02-06 2024-08-15 F. Hoffmann-La Roche Ag Combination therapy and uses thereof
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
CN121079323A (zh) 2023-02-21 2025-12-05 特尼奥生物股份有限公司 c-Kit结合蛋白、嵌合抗原受体及其用途
WO2024175031A1 (zh) 2023-02-21 2024-08-29 江苏恒瑞医药股份有限公司 Il-36r结合蛋白及其医药用途
CN120676969A (zh) 2023-02-27 2025-09-19 苏州盛迪亚生物医药有限公司 抗dll3抗体、其抗体-药物偶联物及其医药用途
KR20250156759A (ko) 2023-02-28 2025-11-03 리제너론 파아마슈티컬스, 인크. 다가 항스파이크 단백질 결합 분자 및 이의 용도
WO2024182540A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof
CN120826234A (zh) 2023-03-06 2025-10-21 豪夫迈·罗氏有限公司 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
CN120858109A (zh) 2023-03-10 2025-10-28 基因泰克公司 与蛋白酶的融合物及其用途
CN120835901A (zh) 2023-03-13 2025-10-24 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
WO2024197157A1 (en) 2023-03-21 2024-09-26 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
KR20250167591A (ko) 2023-03-31 2025-12-01 제넨테크, 인크. 항-알파 v 베타 8 인테그린 항체 및 사용 방법
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
CN120917044A (zh) 2023-04-03 2025-11-07 豪夫迈·罗氏有限公司 激动性拆分型抗体
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024208898A1 (en) 2023-04-05 2024-10-10 Genmab A/S Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4442275A1 (en) 2023-04-06 2024-10-09 ModiQuest B.V. Anti-type ii collagen antibodies
CN121175072A (zh) 2023-04-11 2025-12-19 浙江博锐生物制药有限公司 抗ror1抗体及其药物偶联物
KR20250169618A (ko) 2023-04-13 2025-12-03 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체를 사용하여 림프종을 치료하는 방법
JPWO2024214811A1 (enExample) 2023-04-14 2024-10-17
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
TW202448949A (zh) 2023-05-05 2024-12-16 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
CN121127493A (zh) 2023-05-08 2025-12-12 豪夫迈·罗氏有限公司 靶向干扰素 α 融合蛋白及使用方法
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
AU2024268933A1 (en) 2023-05-10 2025-11-20 Chugai Seiyaku Kabushiki Kaisha Methods and compositions for treating cancer
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
AU2024274130A1 (en) 2023-05-12 2026-01-08 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof
AR132687A1 (es) 2023-05-16 2025-07-23 Hoffmann La Roche Inmunoconjugados de il-2 regulados por pd-1 y sus usos
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
TW202502811A (zh) 2023-06-01 2025-01-16 瑞士商赫孚孟拉羅股份公司 與ｂｃｍａ特異性結合之免疫刺激性抗原結合分子
WO2024246083A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Bispecific antibodies targeting bcma and cd28
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
WO2024258785A1 (en) 2023-06-11 2024-12-19 Regeneron Pharmaceuticals, Inc. Circularized antibody molecules
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白
WO2024256623A1 (en) 2023-06-16 2024-12-19 Heidelberg Immunotherapeutics Gmbh Novel anti-hsv antibody
AU2024311339A1 (en) 2023-06-21 2026-01-08 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2024263845A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Treatment of multiple myeloma
WO2024263761A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Antibodies and uses thereof
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
AU2024307352A1 (en) 2023-06-27 2025-12-11 Amgen Inc. Charge pair mutations to enable correct heavy-light chain pairing
WO2025007037A1 (en) 2023-06-28 2025-01-02 Dragonfly Therapeutics, Inc. Variant il-2 proteins
AR133071A1 (es) 2023-06-30 2025-08-20 Genmab As ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025010272A1 (en) * 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
AR133412A1 (es) 2023-07-30 2025-09-24 Janssen Biotech Inc Moléculas que se unen a la calreticulina mutante y usos de estas
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025038362A1 (en) 2023-08-11 2025-02-20 Merck Sharp & Dohme Llc Monovalent interleukin 12 (il-12) heterodimeric fc proteins
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025042428A1 (en) 2023-08-18 2025-02-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules and uses thereof
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025041077A1 (en) 2023-08-23 2025-02-27 Sanofi Ctla-4-based lysosomal degraders and uses thereof
TW202525856A (zh) 2023-09-08 2025-07-01 美商Ｍｌａｂ生物科學有限公司 雙功能性蛋白質及其用途
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025068957A1 (en) 2023-09-29 2025-04-03 Novartis Ag Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
US20250154287A1 (en) 2023-11-10 2025-05-15 Pfizer Inc. ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025106634A1 (en) 2023-11-17 2025-05-22 Genentech, Inc. Mcl-1 inhibitor compounds and use in antibody drug conjugates
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
WO2025125118A1 (en) 2023-12-11 2025-06-19 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025129010A1 (en) 2023-12-14 2025-06-19 Genentech, Inc. Methods of structure determination using antibodies
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
WO2025137454A1 (en) 2023-12-21 2025-06-26 Amgen Inc. Stabilizing homodimer mutations for two cell heterodimer production
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025199243A1 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Trivalent multispecific binding molecules and methods of use thereof
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025202147A1 (en) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Interleukin-7 immunoconjugates
US20250313641A1 (en) 2024-04-09 2025-10-09 Amgen Inc. Agonistic anti-il-2rbg heavy-chain antibodies
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery
WO2025219504A1 (en) 2024-04-19 2025-10-23 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025233825A1 (en) 2024-05-06 2025-11-13 Janssen Pharmaceutica Nv Enrichment of cells expressing a bird linker
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025233304A1 (en) 2024-05-08 2025-11-13 F. Hoffmann-La Roche Ag Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025237931A1 (en) 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
WO2025240781A2 (en) 2024-05-15 2025-11-20 Werewolf Therapeutics, Inc. Modified antibodies and immunoglobulin formats
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof
WO2025253337A2 (en) 2024-06-05 2025-12-11 Sanofi Monospecific and bispecific tau binding proteins and compositions thereof
WO2025255340A2 (en) 2024-06-05 2025-12-11 Genzyme Corporation BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
WO2025255349A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025255452A2 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses thereof
US20250376524A1 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Tetravalent multispecific binding molecules and methods of use thereof
WO2025259718A2 (en) 2024-06-11 2025-12-18 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
CN121135878A (zh) 2024-06-14 2025-12-16 康诺亚生物医药科技（成都）有限公司 针对ox40l和il-13的双特异性抗体及其用途
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2025261943A1 (en) 2024-06-18 2025-12-26 F. Hoffmann-La Roche Ag Anti-cancer combinations comprising mosperafenib and folfox or folfiri
WO2026006162A2 (en) 2024-06-24 2026-01-02 Genentech, Inc. B vitamin modulation
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK1599504T3 (da) * 2003-02-25 2015-03-09 Vaccibody As Modificeret antistof
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
KR101374454B1 (ko) * 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US8871912B2 (en) * 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
DK2009101T3 (en) * 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
AU2009204501B2 (en) * 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2010063785A2 (en) 2008-12-03 2010-06-10 Genmab A/S Antibody variants having modifications in the constant region
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2012304203A1 (en) * 2011-09-01 2014-03-20 University Of South Australia Patterning method
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138035A (ja) * 2008-01-07 2018-09-06 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃ ｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US11001643B2 (en) 2014-09-26 2021-05-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy

Also Published As

Publication number Publication date
US20100286374A1 (en) 2010-11-11
PL2235064T3 (pl) 2016-06-30
WO2009089004A1 (en) 2009-07-16
EP3061770B1 (en) 2019-12-11
US20140024111A1 (en) 2014-01-23
EP3061770A1 (en) 2016-08-31
AU2009204501A1 (en) 2009-07-16
CA2709847C (en) 2018-07-10
HUE028536T2 (en) 2016-12-28
SI2235064T1 (sl) 2016-04-29
CA2709847A1 (en) 2009-07-16
JP2011508604A (ja) 2011-03-17
AU2009204501B2 (en) 2015-02-12
ES2563027T3 (es) 2016-03-10
JP6328087B2 (ja) 2018-05-23
US8592562B2 (en) 2013-11-26
EP2235064A1 (en) 2010-10-06
CY1117162T1 (el) 2017-04-05
DK2235064T3 (en) 2016-01-11
PT2235064E (pt) 2016-03-01
JP2018138035A (ja) 2018-09-06
ES2774337T3 (es) 2020-07-20
JP2016093175A (ja) 2016-05-26
EP2235064B1 (en) 2015-11-25
JP6703560B2 (ja) 2020-06-03
MX350962B (es) 2017-09-27
EP3061770B8 (en) 2020-02-12
EP3663318A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
JP6703560B2 (ja) 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃ ｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US11208459B2 (en) Constructs having a SIRP-alpha domain or variant thereof
CN107207592B (zh) 结构域交换的抗体
JP2016506377A (ja) 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
AU2021238341A1 (en) Miniature guidance and navigation control (miniGNC) antibody-like proteins and methods of making and using thereof
EP3319996B1 (en) Bispecific and multispecific antibodies and method for isolation of such
US20210054049A1 (en) Variant domains for multimerizing proteins and separation thereof
TWI825544B (zh) 含異二聚體抗體Ｆｃ的蛋白以及其製備方法
KR20230141817A (ko) 이중특이 항체
AU2015202560B2 (en) Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects
JPWO2022166728A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150507

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160114

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170606

R150 Certificate of patent or registration of utility model

Ref document number: 6157046

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250